Prothena announces AFFIRM-AL trial did not meet primary endpoint
Confident Investing Starts Here:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
11 hours ago
- CNBC
Lightning Round: Get on board with Affirm, says Jim Cramer
'Mad Money' host Jim Cramer weighs in on stocks including: Eli Lilly, Affirm, Root, ServiceNow, and more.
Medscape
19 hours ago
- Medscape
Coronary Sinus Reducer Shows Promise, With Caveats
The coronary sinus reducer, an hourglass-shaped stent that narrows the coronary sinus to increase coronary sinus pressure, has shown some promise in treating patients with refractory angina. But a meta-analysis published today in JACC: Cardiovascular Interventions found the benefits of the intervention are likely smaller than those early studies predicted. 'There have been lots of unblinded single-arm studies [of the procedure] but only three randomized controlled trials, so we wanted to look at the different effect sizes to better understand the overall potential efficacy,' said Rasha Al-Lamee, MD, a cardiologist at the National Heart and Lung Institute, part of Imperial College London, London, England, who led the meta-analysis. Al-Lamee and her colleagues looked at data from a combined total of 180 patients in the three trials, as well as 13 single-arm studies with 668 total patients. They found the coronary sinus procedure to be safe, with a success rate of 98.3%. But while both the single-arm and the controlled trials demonstrated improvements in symptoms of angina, the effect size was much smaller in the controlled trials. In the more rigorous trials, 26% of patients experienced at least a one-class improvement and 17% had at least a two-class improvement on the Canadian Cardiovascular Society classification of angina. Those figures were about one third of the gains reported in the single-arm trials. What's more, the randomized controlled trials found no evidence of benefit based on continuous measurements such as the Seattle Angina Questionnaire. Nor did they find improvements in objective measures such as myocardial perfusion associated with the intervention. Deepak Bhatt, MD, a cardiologist at the Icahn School of Medicine at Mount Sinai in New York City, who co-wrote an editorial accompanying the journal article, said more treatment options are needed for patients with refractory angina, who have often exhausted all other medical therapies and surgical procedures. But while coronary sinus reduction shows promise, the meta-analysis demonstrates why more, and larger, trials will be needed before clinicians can use it more broadly. 'It's not an inexpensive procedure, so we want substantial, objectively quantified evidence that it helps patients,' he told Medscape Medical News . 'History is littered with examples of things we were convinced worked but really didn't.' Percutaneous laser therapy, for example, seemed to show benefits for refractory angina at first, but more rigorous randomized trials found no benefit from the procedure, he said. The coronary sinus reducer device is already approved in the UK and Europe and its use is on the rise there, said Al-Lamee, but it has not yet been approved in the US. The ongoing COSIRA-II trial, with an estimated enrollment of 380 patients, should be well-powered enough to provide definitive results and support US approval, she said. Should COSIRA-II show definite benefit, she added, the device may become more of a frontline treatment, used before riskier revascularization options. 'Why have a redo of coronary artery bypass surgery if you have a device that is safe and effective?' she said. Al-Lamee had received consulting and speaker fees from Shockwave Medical, which makes the CSR device. Bhatt reported no relevant financial conflicts.
Yahoo
19 hours ago
- Yahoo
FuturHealth Offers Users Complimentary Access to Apple Fitness+ for Movement and Motivation
SAN DIEGO, Aug. 11, 2025 /PRNewswire/ -- FuturHealth, a leading provider of personalized weight-loss solutions, today announced that it will bring Apple Fitness+, the award-winning fitness and wellness service that is welcoming to all, to members who are enrolled in a FuturHealth program at no additional cost. The offer gives FuturHealth users additional fitness tools to help them reach their goals. This offer underscores FuturHealth's commitment to empowering members with a comprehensive toolkit that supports sustainable, personalized weight loss journeys, whether with medication, nutrition, fitness, or a combination of all three. "Our top priority has always been to help people on a weight loss journey experience real, long-lasting results through holistic lifestyle changes and personalized support," said Luke Mahoney, co-founder and CEO of FuturHealth. "With this Fitness+ offer, users can tap into thousands of workouts and meditations—wherever and whenever they choose—at no extra cost." Fitness+ offers users access to thousands of workouts and meditations in 4K Ultra High Definition on iPhone, iPad and Apple TV, ranging from 5 to 45 minutes across 12 different types including Strength, HIIT, Treadmill, Rowing, Cycling, Yoga, and more. All it takes is an iPhone to get started— and with Apple Watch, users can unlock even more motivation through personalized, real-time metrics right onscreen. Fitness+ workouts feature energizing music playlists by today's top artists all led by a diverse and inclusive team of trainers that can be done anytime, anywhere. Fitness+ also offers inspiring audio experiences including Time to Walk and Time to Run. Users can access the Fitness+ offer by simply tapping on the Apple Fitness+ module on the home screen in the FuturHealth app. This announcement follows a series of significant milestones for the company. This year alone, FuturHealth launched Affirm's flexible payment options for members, partnered with Valisure to ensure the highest quality and safety standards for weight-loss medications, and released compelling efficacy data showing that combining the FuturHealth Program with weight-loss treatments significantly enhances weight loss outcomes compared to medication alone. For more information about FuturHealth's innovative approach, visit About FuturHealth:FuturHealth is your partner in weight loss, providing personalized guidance designed to work with your everyday life. Together with a team of doctors, dietitians, and weight-loss experts, we combine scientifically-proven medications with clinically-crafted, expertly-curated meals for quick, easy, effective, and affordable wins. Founded with a mission to create a holistic and personalized alternative to traditional, one-size-fits-all weight-loss solutions, we meet each person where they are on their unique journey, empowering them to confidently take control of their well-being at every step of the way. With a network of 350+ providers across 48 states, FuturHealth has transformed the lives of over 1.5 million patients and counting. In under a year, it has achieved an extraordinary 980% growth in active patients and facilitated over 6 billion online interactions. View original content to download multimedia: SOURCE FuturHealth
